Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 307 in Vertex

  1. STV Acquires DPMRead the original story

    Thursday Mar 19 | ThomasNet

    ... plan to become a national provider of construction and project management services." Recent DPM projects include: Vertex Pharmaceuticals: managed the relocation from 700,000 square feet of space in 11 different buildings in Cambridge to 1.1 million ...

    Comment?

  2. OCZ Vector 180 ReviewRead the original story w/Photo

    Tuesday Mar 24 | Bit-tech.net

    ... an OCZ Aragon co-processor. It's the same platform used by all its 2.5-inch SSDs, though the lower tier Arc 100 and Vertex drives use the slower M10 version of the controller, while the AMD Radeon R7 SSD sticks with the M00. Like the majority of ...

    Comment?

  3. Jeff Cooper: Biotech and the Dollar BlinkRead the original story w/Photo

    Tuesday Mar 24 | Minyanville

    ... -- late-stage failed breakouts over flat consolidations. Other names in the group that reversed strongly include Vertex Pharmaceuticals (VRTX) and Medivation (MDVN). So there was selling across the board in the big cap and small cap bios. ...

    Comment?

  4. Why Investors Shouldn't Freak Out Over Vertex's Latest Trial ResultsRead the original story

    Monday Mar 23 | BioSpace

    Results of a small study of what could become the third cystic fibrosis drug to come out of Vertex Pharmaceuticals showed the drug worked about as well as the Boston biotech's second potential drug, approval of which is expected this spring. But investors were apparently hoping for more.

    Comment?

  5. US stocks slip as transports' decline offsets consumer gainsRead the original story

    Monday Mar 23 | West Hawaii Today

    ... reducing a January outlook forecasting a mid-single-digit increase. Union Pacific and CSX lost more than 3.9 percent. Vertex Pharmaceuticals dropped 4 percent after the company said its cystic fibrosis drug Kalydeco combined with an experimental ...

    Comment?

  6. Vertex Tumbles As Cystic Fibrosis Data DisappointsRead the original story w/Photo

    Monday Mar 23 | Investor's Business Daily

    Vertex reported data from a midstage study combining drug candidate VX-661 with the already-marketed ivacaftor, branded Kalydeco, in patients with cystic fibrosis caused by homozygous F508del mutation. As IBD reported in our roundup of upcoming clinical-trial news last week, Vertex's other products already treat this population, but the firm is hoping VX-661 can be expanded into the larger heterozygous F508del mutation population.

    Comment?

  7. Why you shouldn't read too much into the latest Vertex trial resultsRead the original story w/Photo

    Monday Mar 23 | Business Journal

    Results of a small study of what could become the third cystic fibrosis drug to come out of Vertex Pharmaceuticals showed the drug worked about as well as the Boston biotech's second potential drug, approval of which is expected this spring.

    Comment?

  8. Vertex Pharmaceuticals (VRTX) Stock Falls Today on Cystic Fibrosis Drug Trial DataRead the original story w/Photo

    Monday Mar 23 | TheStreet.com

    ... analysts' expectations in a mid-stage trial. Patients who took Kalydeco, also known as ivacaftor, in combination with Vertex's VX-661 experimental drug experienced a 4.4% increase in the amount of air they could exhale in 1 second. This measurement ...

    Comment?

  9. Nasdaq 100 Movers: VRTX, VIPRead the original story w/Photo

    Monday Mar 23 | Forbes.com

    ... Year to date, VimpelCom registers a 31.8% gain. And the worst performing Nasdaq 100 component thus far on the day is Vertex Pharmaceuticals (VRTX), trading down 5.6%. Vertex Pharmaceuticals is showing a gain of 4.1% looking at the year to date ...

    Comment?

  10. S&P 500 Movers: VRTX, GNWRead the original story w/Photo

    Monday Mar 23 | Forbes.com

    ... Financial has lost about 8.6% of its value. And the worst performing S&P 500 component thus far on the day is Vertex Pharmaceuticals (VRTX), trading down 6.6%. Vertex Pharmaceuticals is showing a gain of 3.0% looking at the year to date performance. ...

    Comment?

  11. Thomson Reuters Names Most Promising Drugs of 2015Read the original story

    Sunday Mar 22 | Freshnews

    ... (palbociclib) Pfizer breast cancer 2.756 -------------------- ------ ------------- ----- lumacaftor plus ivacaftor Vertex Pharmaceuticals cystic fibrosis 2.737 --------------- ---------------------- --------------- ----- Viekira Pak (veruprevir, ...

    Comment?

  12. STV Acquires DPMRead the original story w/Photo

    Friday Mar 20 | CE News

    ... consistent with STV's strategic plan to become a national provider of construction and project management services." Vertex Pharmaceuticals: managed the relocation from 700,000 square feet of space in 11 different buildings in Cambridge to 1.1 ...

    Comment?

  13. Vertex Inc. Named Top Place to WorkRead the original story

    Friday Mar 20 | Freshnews

    Vertex ranks 11 out of 30 large organizations named to the list this year in the Philadelphia Region and third highest among private companies. This is the second time that Vertex participated in the survey and was named to the list since 2010.

    Comment?

  14. Friday Sector Laggards: Healthcare, IndustrialRead the original story w/Photo

    Friday Mar 20 | Forbes.com

    ... midday Friday is the Healthcare sector, higher by 0.6%. Within that group, Tenet Healthcare Corp. ( NYSE: THC ) and Vertex Pharmaceuticals, Inc. ( NASD: VRTX ) are two of the day's laggards, showing a loss of 2.1% and 1.9%, respectively. Among ...

    Comment?

  15. Poll Finds Massive Support for Boston Biotech After Vertex MoveRead the original story

    Wednesday Mar 18 | BioSpace

    March 19, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor The results of BioSpace 's recent Biotech Temperature Poll are in and Boston , we heard you loud and clear! The vast majority of respondents said they did not think Vertex Pharmaceuticals ' decision to vacate 313,000 square feet of space in the Genetown area meant that Big Biotech will be fleeing Boston . In fact, when asked if Vertex will consolidate its operations in Boston , 81 percent of the 502 respondents said they believed the company would stay.

    Comment?

  16. Thursday Sector Leaders: Healthcare, Technology & CommunicationsRead the original story w/Photo

    Thursday Mar 19 | Forbes.com

    ... from NYU. The best performing sector as of midday Thursday is the Healthcare sector, up 0.3%. Within that group, Vertex Pharmaceuticals, Inc. ( NASD: VRTX ) and AbbVie Inc. ( NYSE: ABBV ) are two large stocks leading the way, showing a gain of 2.5% ...

    Comment?

  17. A Growing Label Drives Vertex's TransformationRead the original story w/Photo

    Thursday Mar 19 | Investopedia

    ... was short. Competitors came through with better next-generation drugs, demolishing Incivek sales and forcing Vertex Pharmaceuticals to transform itself. Today, thanks to ongoing FDA label expansions for its fast-growing Kalydeco, the company has ...

    Comment?

  18. Major cystic fibrosis breakthrough made: Drug combination improves lung functionRead the original story

    Jun 25, 2014 | Science Daily

    ... have led pivotal studies of a new treatment for people with Cystic Fibrosis. The combination therapy, developed by Vertex (a Boston, USA company), improves lung function and reduces hospitalizations for patients with the most common type of cystic ...

    Comment?

  19. a Five Things You Need to Know: Take 'T' to Work Day; Akamai to...Read the original story w/Photo

    Thursday Mar 19 | Business Journal

    ... among tech and life sciences companies moving to Boston, a list that over the past few years includes Zipcar and Vertex Pharmaceuticals , and most recently Harmonix, maker of the video game "Rock Band, which will move its headquarters from Cambridge ...

    Comment?

  20. Vertex Gets FDA Approval of KALYDECOA for Children with Cystic FibrosisRead the original story w/Photo

    Wednesday Mar 18 | Pharmaceutical Processing

    Vertex Pharmaceuticals has announced that the U.S. Food and Drug Administration approved KALYDECO A for use in children ages 2 to 5 with cystic fibrosis who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator gene . Prior to today's approval, KALYDECO was approved in the United States for people ages 6 and older with these mutations.

    Comment?